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Key Points
•Human ILC1-like cells
kill tumors in a KIR-
independent manner.
• The cytotoxicity of hu-
man ILC1-like cells is
impaired in AML at di-
agnosis but is restored
in remission.
Anunderstanding of natural killer (NK) cell physiology in acutemyeloid leukemia (AML) has led
to the use of NK cell transfer in patients, demonstrating promising clinical results. However,
AML is still characterized by a high relapse rate and poor overall survival. In addition to
conventionalNKs that canbe considered the innate counterparts of CD8Tcells, another family of
innate lymphocytes has been recently described with phenotypes and functions mirroring
thoseofhelperCD4Tcells.Here, inbloodandtissues,we identifiedaCD561 innate cell population
harboring mixed transcriptional and phenotypic attributes of conventional helper innate
lymphoid cells (ILCs) and lytic NK cells. These CD561 ILC1-like cells possess strong cytotoxic
capacities that are impaired in AML patients at diagnosis but are restored upon remission. Their
cytotoxicity is KIR independent and relies on the expression of TRAIL, NKp30, NKp80, and
NKG2A. However, the presence of leukemic blasts, HLA-E–positive cells, and/or transforming
growth factor-b1 (TGF-b1) strongly affect their cytotoxic potential, at least partially by reducing
the expression of cytotoxic-related molecules. Notably, CD561 ILC1-like cells are also present
in the NK cell preparations used in NK transfer–based clinical trials. Overall, we identified an
NK cell–related CD561 ILC population involved in tumor immunosurveillance in humans, and
we propose that restoring their functions with anti-NKG2A antibodies and/or small molecules
inhibiting TGF-b1 might represent a novel strategy for improving current immunotherapies.
Introduction
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with a 3.7/100 000
incidence per year. AML has a high relapse rate, which decreases patients’ 5-year overall survival to
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19%.1 The conventional treatments consist of chemotherapy or
allogeneic hematopoietic stem cell transplantation.2 Moreover,
natural killer (NK) cell transfer therapy has been developed and
provides good outcome improvement if the donor and recipient
are KIR mismatched.3-6
In addition to conventional NKs (cNKs), another lymphocytic innate
cell family has recently been identified and named innate lymphoid
cells (ILCs). ILCs constitutively express the interleukin-7 (IL-7)
receptor a chain (CD127) and are deprived of somatically rearranged
antigen-specific receptors and common lineage markers. Whereas
cNKs functionally mirror adaptive CD8 T cells, conventional ILCs
are considered the innate counterpart of helper CD4 T cells7; ILCs
secrete pro- or anti-inflammatory cytokines upon sensing the
microenvironment and “help” effector cells.7-11
Despite the clear-cut ILC subset delineation, unexpected pheno-
typic and functional heterogeneity within NK and ILC subsets has
recently been reported,12-15 opening novel opportunities for innate
cell-based immunotherapies.
Here, we describe an unconventional human ILC1-like cell population
with cytotoxic properties that expresses the ILC marker CD127 and
CD5616,17 but lacks CD16 and c-Kit (CD117) expression. These
CD561 ILC1-like cells are related to the stage 4b (S4b) NK cells.
Their cytolytic mechanism is KIR independent but requires NKp80,
NKp30, and TRAIL engagement to lyse both major histocompatibility
complex class I (MHCI) positive and negative targets. Similar
to previous reports of conventional ILCs18,19 and NKs,20 the
frequency and functions of CD561 ILC1-like cells are impaired in
AML patients. At diagnosis, CD561 ILC1-like cells are signifi-
cantly reduced, and their killing capacity is defective due to the
persistence of NKG2A expression, the inability to release cytotoxic
mediators, and the downregulation of NKp80, NKp30, and TRAIL,
which is at least partially mediated by transforming growth factor-b
(TGF-b). Notably, during remission, the cytotoxic machinery and
the receptors’ expression on CD561 ILC1-like are completely
restored.
Overall, we propose that this CD561 ILC1-like cell population
represents an attractive target for immunomodulatory drugs, such
as anti-NKG2A antibodies and TGF-bRI inhibitors, in AML patients.
Given the presence of these cells in NK-cell preparations used
for adoptive transfer, exploiting their properties might provide
a powerful approach for maximizing the efficacy of KIR-mismatch
independent immunotherapy.
Methods
All the methods used in this article are described as supplemental
Information.
Results
CD561CD162 ILC1-like cells have NK properties and
are impaired in AML patients at diagnosis
We recently reported that the ILC1 compartment is numerically
and functionally impaired in AML patients at diagnosis.19 Here, we
identify a CD162 CD1271 c-Kit2CRTH22CD561 cell population,
which falls in the ILC1 gate (Figure 1A-B).21t- t-SNE analysis based
on CD127, CD56, CD16, CRTH2, and c-Kit expression is sufficient
to clearly discriminate this cell population from conventional ILC
(ILC1, ILC2, and “ILC progenitors” [ILCP]22) and NK subsets
(Figure 1C). In particular, their CD56dim CD162 CD1271 c-Kit2
phenotype distinguishes them from the conventional CD56bright and
CD56dim NK subsets (Figure 1D). Of note, CD561 ILC1-like cells
do not express CD49a (supplemental Figure 1).
In AML patients at diagnosis (n 5 60, [35 to 97 years old];
supplemental Table 1), the proportions of this population among
lymphocytes are strongly reduced (Figure 1E-F), independently
of the patients’ age (data not shown). The CD56dim NK compart-
ment is also impaired, whereas the CD56bright NK cell proportions
are comparable between the patients and healthy donors (HDs)
(Figure 1E-F).
In the HDs (n 5 47, median age 48, interquartile range 31 to 64),
CD561 ILC1-like cells represent 38.5% of all Lineage2 CD1271
cells in the peripheral blood (range 9.4% to 69.0%; Figure 1G).
Similar to the cNK frequencies, which are known to be influenced
by age,23-25 compared with the other “helper” ILCs, we observed
a significant CD561 ILC1-like increase in the elderly donors
(Figure 1H). The analysis of ILC frequencies within lymphoid
and nonlymphoid organs from HDs and cadavers shows that
CD561 ILC1-like cells are also present in those tissues
(Figure 1I).
We then evaluated the CD561 ILC1-like cytokine profile in
response to IL-12, IL-15, and IL-18 stimulation (n 5 4). When
stimulated, these cells secrete interferon-g and IL-8, the latter
distinguishing them from the CD56dim NKs (supplemental
Figure 2A-B).
RNA sequencing reveals a CD561 ILC1-like cell
transcriptomic signature
To investigate specific CD561 ILC1-like cell features, we performed
an RNA-sequencing analysis of highly pure ILC and cNK subsets
from the peripheral blood of HDs (n5 3) (supplemental Figure 3A-B).
In a principal component analysis of the ILC and NK subsets for their
expression of cNKmarkers, CD561 ILC1-like cells appear to bemore
closely related to CD56bright NKs and ILCP than ILC1, ILC2, and
CD56dim NKs (Figure 2A; supplemental Figure 3C-D).
We then analyzed their transcription factor profile at RNA level.
These cells express similar levels of TBX21 (T-bet), EOMES,
and RUNX3 transcripts as cNKs. Their expression of ZBTB16
(promyelocytic leukemia zinc finger protein [PLZF]) and aryl
hydrocarbon receptor (AHR) transcripts is intermediate com-
pared with CD56bright and CD56dim NKs. However, CD56dim
NKs express higher levels of NFIL3 transcripts than CD561
ILC1-like cells (Figure 2B). Furthermore, a principal component
analysis reveals that the expression of PLZF, GATA3, Eomes,
RORgt, and T-bet at protein level is sufficient to discriminate
CD561 ILC1-like cells from the other ILC and NK subsets
(supplemental Figure 3E-H).
Then, we analyzed the 100 genes with the lowest or highest log fold
change between the CD561 ILC1-like cells and conventional
ILC/NK subsets (Figure 2C). The CD561 ILC1-like cells display
higher levels of NK-associated transcripts than ILC1, ILC2, and
ILCP (eg, EOMES, KLRD1, KLRC2, and KLRF1). CD561 ILC1-like
cell transcriptomic signature includes genes encoding cytokine
receptors and chemokine receptors. By associating Gene Ontology
(GO) pathways to each of the differentially expressed genes, we
observed that they are mostly involved in lymphocyte activation (GO
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Figure 1. Identification of a CD561 ILC1-like population with NK properties that is impaired in AML patients at diagnosis. (A-B) Representative density plots of
the extracellular flow cytometry panel used to identify the cNK cell subsets (A) and the ILC subsets (B) in peripheral blood (PB) mononuclear cells (PBMCs; ILC1 as CRTH22
c-Kit2 CD562, ILC2 as CRTH21 c-Kit1/2 CD561/2, ILCP as CRTH22 c-Kit1 CD561/2, and cNKs as CD162 CD56bright and CD161 CD56dim).21,22 Lineage markers used
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pathway GO0046649), immune effector process (GO0002252),
leukocyte migration (GO0050900), and metabolism (GO0008152).
To confirm that CD561 ILC1-like cells display a specific metabolism
compared with the conventional ILC and NK subsets, we evaluated
their nutrient uptake and mitochondrial activity (supplemental
Figure 4). The CD561 ILC1-like cells display a lower glucose
analog (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deox-
yglucose) uptake than the ILC2 and cNKs and a higher fatty
acid uptake than the CD56dim NKs. To assess their specific
mitochondrial activity, we evaluated the ratio of the uptake of
MitoTracker deep red to that of MitoTracker green.26 The ratio in
CD561 ILC1-like cells is higher than in the ILC1 and tend to be
higher compared with cNKs. Hence, the distinct metabolic
transcriptional pattern of CD561 ILC1-like cells is reflected by
their specific nutrient uptake and mitochondrial activity.
CD561 ILC1-like cells are cytotoxic effectors
regulated by the NKp30, NKp80, TRAIL, and
HLA-E pathways
Based on the CD561 ILC1-like cell-specific transcriptomic signature
involving genes participating in immune effector processes and
lymphocyte activation, we directly evaluated the CD561 ILC1-like cell
cytotoxic activity (Figure 3). CD561 ILC1-like cells express NKp30,
NKp80, CD94/NKG2A, and DNAM-1 at a high level, whereas low
levels of NKp44, NKp46, and NKG2C were observed (Figure 3A).
TRAIL expression is comparable between the CD561 ILC1-like cells
and CD56bright NKs but varies depending on the donor’s age (data
not shown). Subsequently, we aimed to ascertain whether CD561
ILC1-like cells contain death-inducing mediators. We observed
a significant CD561 ILC1-like cell production of granzymes A,
B, K, and M, perforin and granulysin, with the highest levels
measured for granzyme A and M (Figure 3B; supplemental
Figure 5A). Next, we cocultured CD561 ILC1-like cells with
the standard NK-sensitive MHCI2 K562 cell line (Figure 3C).
After 4 hours, CD561 ILC1-like cells upregulate CD107a,
demonstrating their ability to degranulate. To confirm their
cytotoxicity, we analyzed CD561 ILC1-like cell-mediated target
lysis using 51Cr-release assays. CD561 ILC1-like cells lyse
K562 to an extent comparable to that of cNKs, whereas the
helper ILCs fail to induce any target cell lysis (Figure 3D). In
accordance with the absence of KIR receptors, CD561 ILC1-
like cells are also able to lyse the MHCI1 BJAB and U937 cell
lines (Figure 3E; supplemental Figure 5B). To investigate whether
DNAM-1, NKp30, NKp80, and TRAIL, which are expressed at the
highest levels by CD561 ILC1-like cells (Figure 3A), are involved
in cytotoxicity, we cocultured CD561 ILC1-like cells with targets
in the presence of specific blocking reagents (Figure 3F). The
addition of anti–DNAM-1 blocking antibodies does not af-
fect the CD561 ILC1-like cell killing potential. However, the
presence of anti-NKp30 blocking antibodies strongly reduces
their killing activity. We also confirmed that TRAIL is involved
in their cytotoxicity as the CD561 ILC1-like cell-mediated
killing of the TRAIL-sensitive BJAB line27-29 was decreased in
the presence of a TRAIL decoy receptor. Subsequently, we
cocultured the CD561 ILC1-like cells with the U937 line, which
expresses the ligand for NKp80 (ie, Activation-Induced C-type
Lectin (supplemental Figure 5C). The addition of NKp80 blocking
antibodies decreases the CD561 ILC1-like cell-killing capac-
ity. Finally, based on the high expression of CD94/NKG2A by
CD561 ILC1-like cells (Figure 3A), we compared the CD561
ILC1-like cell-mediated lysis of wild-type (HLA-E negative) and
HLA-E–transfected (HLA-E1) 721.221 tumor cells (Figure 3G;
supplemental Figure 4D). CD561 ILC1-like cell cytotoxicity is
impaired when the targets express HLA-E. Overall, we show
that CD561 ILC1-like cells display high cytotoxicity triggered by
the NKp30, NKp80, and TRAIL pathways and inhibited upon
HLA-E binding.
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Figure 1. (Continued). for the “helper” ILC staining include CD3, CD4, CD8, CD14, CD15, CD16, CD19, CD20, CD33, CD34, CD203c, and FceRIa; same
lineage markers, except for CD16, were used for the cNK staining. (C) CD127, CD56, CD16, CRTH2, c-Kit fluorescence intensity on ILC and NK subsets were
concatenated from 5 HDs and analyzed with t-distributed stochastic neighbor embedding (t-SNE). c-Kit, CD127, CD56, CD16 expression levels on ILC1, CD561
ILC1-like cells and NKs are represented in panel D. Representative gating (E) and quantification of CD561 ILC1-like cell and cNK proportions among lymphocytes in
blood from HDs and AML patients at diagnosis (F) (CD561 ILC1-like cells: HD, n 5 47; AML patients: n 5 60; cNKs: HD: n 5 12, AML: n 5 18). (G) Summary of the
results of the total ILC proportions and ILC1, ILC2, ILCP, and CD561 ILC1-like cell subset frequencies among the total ILCs in HD peripheral blood (N 5 47, age
median 48, interquartile range 31 to 64). (H) Correlation between ILC subsets’ relative frequencies in blood and age (cord blood: n 5 9, children: n 5 6, [3 to 12] years
old, adults: n 5 47, age mean 48). (I) CD561 ILC1-like cell relative frequencies among the total ILCs in tissues from healthy adults (n 5 3-18). Spearman
correlations were used in panel H. One dot 5 1 donor. Mann-Whitney unpaired U tests were used in panel F. ****P , .0001. BM, bone marrow; LN, lymph node.
ns, not significant.
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Figure 2. Transcriptomic signature of
ex vivo CD561 ILC1-like cells in peripheral
blood from HDs. (A) Principal component
analysis (PCA) of ex vivo fluorescence-activated
cell–sorted ILC and NK subsets from HDs
peripheral blood (n 5 3). (B) Heat map of z
scores of the expression levels of genes encod-
ing ILC/NK transcription factors (n 5 3). (C)
Heat map of log counts per million (CPM) of the
100 most differentially expressed genes be-
tween CD561 ILC1-like cells and ILC1, ILC2,
ILCP, CD56bright NKs or CD56dim NKs. The GO
pathway to which each gene belongs is repre-
sented at the left of each heat map: Metabolic
process GO0008152 (“Metabolism"); Lympho-
cyte activation GO0046649 (“Activation”); Leu-
kocyte migration GO0050900 (“Migration”);
Immune effector process GO0002252 (“Effec-
tor”). Max, maximum; Min, minimum.
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Figure 3. CD561 ILC1-like cells are cytotoxic effectors regulated by the NKp30, NKp80, TRAIL, and HLA-E pathways. (A) Extracellular flow cytometry analysis of NK
receptor expression in ILCP, CD561 ILC1-like cells, and cNKs (n 5 4-18). (B) Intracellular flow cytometry was performed using HD PBMCs to assess CD561 ILC1-like cell
production of granzyme A (n 5 15), granzyme B (n 5 15), granzyme K (n 5 12), granzyme M (n 5 12), perforin (n 5 12), and granulysin (n 5 12). (C) Extracellular flow
cytometry was performed after a 4-hour coculture of ILC/NK-enriched PBMCs with K562 (ratio E:T 1:1), anti-CD107a, and Golgistop to assess CD561 ILC1-like cell de-
granulation (n 5 16). (D) Specific lysis of the K562 tumor cell line by CD561 ILC1-like cells, cNKs, and helper ILCs (results in duplicate). (E) Specific lysis of the U937, K562,
and BJAB tumor cell lines by CD561 ILC1-like cells (results in duplicate). (F) Specific lysis by CD561 ILC1-like cells of K562 (ratio E:T 20:1), BJAB (ratio E:T 20:1), and U937
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CD561 ILC1-like cells possess common features with
NK cell developmental intermediates
Freud and colleagues recently showed that ILC3 and NKs share
a common progenitor that is distinct from ILC2 progenitors.30
They also demonstrated that S4a NK developmental intermedi-
ates possess both NK- and ILC3-related characteristics.31 We
thus compared the CD561 ILC1-like cells with the NK de-
velopmental intermediates in terms of phenotype, based on their
previously published data31 (Table 1). NKp80 is acquired in NKs
upon maturation from the S4b stage, alongside the production
of cytotoxic mediators. Based on their expression of NKp80 and
cytolytic activity, CD561 ILC1-like cells are more mature than
the S3 and S4a NK cells. However, being CD16-negative, these
cells are clearly distinct from S5 NKs. CD561 ILC1-like cells
share similar features with S4b NKs, because they express
CD94/NKG2A heterodimers, NKG2D, CXCR3, and CD122,
while being devoid of KIR receptors in blood. However, S4b NKs
are reportedly CD127low/2 and c-Kit1/2. S4b mainly comprises
CD56bright NKs, which have a distinct transcriptomic profile compared
with CD561 ILC1-like cells (Figure 2C). In order to formally evaluate
the capacity of CD561 ILC1-like cells to differentiate into other ILC
subsets or NK developmental stages, we sorted these cells and
cultured them on OP9 stromal cells in the presence of IL-7 with or
without the addition of IL-15 (supplemental Figure 6A-B). Their
phenotype was analyzed after 10 days. The CD162 CD94high
c-Kit2 cell population remains the major one upon culture, in
particular, in the presence of IL-15. Two minor cell populations
emerge by the upregulation of CD16 or c-Kit. Next, to determine
whether CD561 ILC1-like cells represent an effector population
generated in the periphery, we monitored their presence in human
fetal tissues and during immune reconstitution in humanized mice.
CD561 ILC1-like cells were detectable in all human fetal tissues
analyzed (supplemental Figure 6C) and could be identified as early
as 8 weeks postreconstitution in humanized mice (supplemental
Figure 6D-E). To further dissect their developmental requirement,
we monitored the CD561 ILC1-like cell frequencies in patients
with severe combined immunodeficiency (supplemental Figure 6F-G).
As conventional ILCs and NKs, CD561 ILC1-like cells require
JAK3 and ADA genes for their development, whereas they are
able to develop in the absence of ARTEMIS and CD3D genes.
We identified CD561 ILC1-like cells and cNKs, yet at reduced
levels, in an IL2RG-deficient patient, suggesting a hypomorphic
mutation with reduced penetrance.32,33 These cells, as cNKs
and helper ILCs, are also present in a RAG1-deficient patient,
whereas they are decreased in a RAG2-deficient patient, in
contrast to cNK and helper ILCs. RAG1 is expressed in common
lymphoid progenitors that are committed to the NK lineage34 and
might thus be required for the differentiation of CD561 ILC1-like
cells. The absence of CD561 ILC1-like cells in the RAG1-
deficient patient might also be due to the ILC and NK genomic
instability observed in mice upon RAG deficiency.35 Overall,
these results suggest that CD561 ILC1-like cells are related to
S4b NK cells and therefore might share similarities with cNKs in
terms of development.
CD561 ILC1-like cytotoxicity is impaired in AML
patients at diagnosis
In order to evaluate the role of CD561 ILC1-like cells in AML
disease, we investigated their cytotoxic profile at diagnosis. The
CD561 ILC1-like cell expression of TRAIL, NKp30, and NKp80
is strongly reduced in the patients compared with HDs (Figure 4A).
Notably, TRAIL and NKp80 are specifically decreased in the
CD561 ILC1-like cells but not in the cNKs. Then, we analyzed the
CD561 ILC1-like cell release of cytotoxic mediators. The patients’
CD561 ILC1-like cells produce amounts of granzymes A, B, and K
and perforin that are similar to those in the HDs, but no granulysin
is produced. In contrast, the granulysin levels in the cNKs are not
impaired in the patients, and the granzyme A level is even increased
in CD56bright NKs in AML (Figure 4B). The degranulation of CD561
ILC1-like cells in AML is significantly impaired as assessed in
cocultures with the K562 line or autologous blasts (Figure 4C-D).
This impairment could be explained by the regulation of CD561
ILC1-like cell cytotoxicity through NKp30, TRAIL, NKp80, or HLA-E
in the case of primary AML blasts. Indeed, we observed HLA-E
expression in primary AML blasts and NKG2A expression in patients’
CD561 ILC1-like cells, suggesting that the HLA-E/CD94-NKG2A
pathway negatively regulates CD561 ILC1-like cells (Figure 4E-F).
In line with this, in the patients, the CD94/NKG2A expression is
preserved on CD561 ILC1-like cells. Overall, we show that the
CD561 ILC1-like cell cytotoxic machinery is impaired in AML
patients at diagnosis, suggesting that these cells are unable to
limit AML oncogenesis.
Table 1. Extracellular phenotype of CD561 ILC1-like cells compared
to previously published NK development stage phenotypes
Marker S3 S4a S4b S5 CD561 ILC1-like
CD16 2 2 2 1 2
CD56 1/2 1 1 1 1
CD127 1 1/2 Low/2 2 1
c-KIT 1 1/2 1/2 1/2 2
CD94 2 1 1 1/2 1
NKG2A 2 1 1 1 1
NKG2C 2 2 1/2 1/2 1/2
NKG2D 2 1 1 1 1
KIR2D 2 2 2 1 2
NKp80 2 2 1 1 1
CXCR3 2 1/2 1 1 1
CD122 2 1 1 1 1
Perforin 2 2 1 1 1
Granzyme A 2 2 1/2 1 1
Granzyme B 2 2 1/2 1/2 1
Granzyme K 2 2 1 1 1
+, expression of the marker; 2, no expression of the marker; Low, low expression of the
marker.
Figure 3. (continued) (ratio E:T 10:1) tumor cell lines in the presence of anti-DNAM-1, anti-NKp30, and anti-NKp80 blocking antibodies or TRAIL decoy receptor.
(G) Specific lysis of wild-type (WT) or HLA-E–transfected 721.221 tumor cell lines by CD561 ILC1-like cells (results in triplicate). One dot 5 1 donor. Statistical tests used for
analyses: panel B: Mann-Whitney unpaired U test; panel C: Wilcoxon paired t test, panel G: multiple Holm-Sidak t tests. *P , .05, **P , .01, ***P , .001, ****P , .0001.
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Figure 4. CD561 ILC1-like cell cytotoxicity is impaired in AML patients at diagnosis. (A) TRAIL, NKp30, and NKp80 expression in CD561 ILC1-like cells and cNKs
in HDs (CD561 ILC1-like: n 5 12-18, cNKs: n 5 11-15) and AML patients at diagnosis (CD561 ILC1-like: n 5 11-20, cNKs: n 5 8-10) by extracellular flow cytometry. (B)
Intracellular flow cytometry was performed using PBMCs from AML patients at diagnosis to assess granzyme A (n 5 4), granzyme B (n 5 4), granzyme K (n 5 4), perforin
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CD561 ILC1-like cell cytotoxicity is restored in AML
patients during remission and might be modulated by
leukemic blasts and TGF-b1
The CD561 ILC1-like cell proportions in the AML patients
at diagnosis and during remission are comparable (n 5 14)
(Figure 5A). However, we observed a trend toward a CD561
ILC1-like cell increase upon remission in 5 of 7 patients with
paired diagnosis/remission peripheral blood samples (Figure 5B).
Then, we evaluated the CD561 ILC1-like cell degranulation potential in
the AML patients during remission. Notably, the CD561 ILC1-like cell
degranulation capacity toward the K562 cells is restored in remission
(Figure 5C). As we previously showed that TRAIL, NKp30, and NKp80
were involved in CD561 ILC1-like cell cytotoxicity (Figure 3F) and that
their expression was decreased in CD561 ILC1-like cells from AML
patients at diagnosis (Figure 4A), we investigated their expression
in CD561 ILC1-like cells in remission (n5 6) (Figure 5D). Interestingly,
the expression of these molecules is restored in the patients during
remission.
We aimed to explore the putative mechanism(s) inhibiting the
cytotoxicity of CD561 ILC1-like cells in patients. To determine
whether AML blasts directly impair CD561 ILC1-like cell functions,
we removed the leukemic blasts from PBMCs from AML patients at
diagnosis and cultured the blast-depleted cells for 24 hours.
Although NKp30 and NKp80 expression is not modulated by the
absence of blasts, TRAIL expression is upregulated in the CD561
ILC1-like cells following blast removal (Figure 5E). A positive
correlation was observed between the circulating AML blast
frequencies and the extent of TRAIL restoration following blast
removal (Figure 5F). To identify potential candidates leading to the
CD561 ILC1-like cell impaired function in AML, we cultured CD561
ILC1-like cells from HDs with different inhibitory molecules known to
be involved in the AML immunosuppressive microenvironment.
Interestingly, we observed that the TRAIL and NKp30, but not
NKp80, expression levels are decreased following a 24-hour culture
with human recombinant TGF-b1 (Figure 5G). TGF-b1 possibly
binds TGF-bR, which we found to be expressed on CD561 ILC1-like
cells (Figure 5H). We also found circulating TGF-b1 in the patient
serum (Figure 5I). An analysis of data from TCGA shows that overall
survival is lower in the patients with a high TGF-b1 expression level
(Figure 4J), in line with its immunosuppressive effect.37 We thus
hypothesize that TGF-b1 might impair CD561 ILC1-like cell
cytotoxicity in AML patients. AML blasts have been shown to
produce AhR ligands.38 We thus incubated NK/ILC-enriched
PBMCs from HDs with the AhR ligand FICZ overnight in the presence
of IL-2 and evaluated its impact on cNKs and CD561 ILC1-like cell
degranulation toward K562 (supplemental Figure 7A). AhR ligand
slightly decreases the degranulation capacity of CD561 ILC1-like
cells and CD56dim NKs in 5 out of 8 donors. Preincubating
NK/ILC-enriched PBMCs with the AhR agonist before IL-12, IL-15,
and IL-18 stimulation also impairs CD561 ILC1-like cell function, in
terms of their interferon-g production (supplemental Figure 7B).
Overall, CD561 ILC1-like cell cytotoxicity in AML might be impaired
by TGF-b1 and AhR ligands and is restored upon remission.
CD561 ILC1-like cells are present in NK-cell
preparations used for NK-cell transfer therapy
Finally, because CD561 ILC1-like cells constitutively express the
CD56 marker (Figure 1B), we hypothesized that these cells might
be present in NK preparations used for NK cell transfer to AML
patients. Indeed, haploidentical NK cell transfer consists of
injecting enriched CD32CD561 haploidentical cells.3-6 To verify
this hypothesis, we applied NK cell purification protocols used for
transfer therapy to PBMCs from HDs (n 5 10). After the 2-step
purification process used in the clinical setting, we evaluated the
presence of ILCs in the preparation by flow cytometry. Interestingly,
the fraction of purified CD32CD561 cells contains CD561 ILC1-like
cells in addition to CD162CD56bright and CD161CD56dim cNKs
(Figure 6A-B). Of note, the CD561 ILC1-like cell phenotype is
conserved after the enrichment (Figure 6C). Therefore, cytotoxic
CD561 ILC1-like cells are present in cell preparations used for the
haploidentical transfer of NK cells in AML patients.
Discussion
We report the identification of an unconventional CD1271 CD561
c-Kit2 ILC population sharing features with both ILCs and S4b NKs.
This innate effector cell type might represent an attractive target for
expanding the current options of immunotherapy for AML patients,
whose prognosis remains overall unsatisfactory.36
Despite their relatedness with helper ILCs and cNKs in terms of
nomenclature, we observed that CD127, c-Kit, CD56, CRTH2, and
CD16 expression at protein level are sufficient to discriminate these
CD561 ILC1-like cells. RNA sequencing of these cells shows distinct
transcriptomic signature compared with helper ILCs and cNKs.
CD561 ILC1-like cells share similar features with S4b NK cells in
terms of phenotype and function, based on published data.30,31
However, the S4b NK cells are reported to be CD127low/2. Upon
culture on OP9 stromal cells, CD561 ILC1-like cells are able to
partially differentiate into both S5 and S4a NK cells. This finding is
consistent with their closeness to S4b NKs known to differentiate
into S5 NKs. Future studies should further compare the differen-
tiation potential of CD561 ILC1-like cells and S4b NK cells using
OP9 stromal cell culture and humanized mice. The dynamics
of transcription factor expression by CD561 ILC1-like cells
throughout the differentiation process and in disease should be
further assessed in humanized mice and in AML patients. Based
on current data, we hypothesize that CD561 ILC1-like cells
might represent a developmental intermediate subpopulation
between ILCs and NK cells. CD561 ILC1-like cells are present
at fetal stage, yet their proportion increases with the age, suggesting
an age-driven maturation of these cells. ILCs and NK cells lack the
requirement for prior sensitization or exposure to elicit a response to
a pathogen or tumor. We offer a hypothesis that CD561 ILC1-like
Figure 4. (continued) (n 5 4), and granulysin (n 5 7) expression in the CD561 ILC1-like cells and cNKs. The results are compared with the values obtained in the HDs.
(C-D) CD107a expression in CD561 ILC1-like cells is assessed by flow cytometry after a 4-hour incubation of ILC/NK-enriched PBMCs from HDs (n 5 16) or AML patients at
diagnosis (n 5 4-13) with medium, the K562 tumor cell line, or blasts at a ratio of 1:1. Representative density plot of CD107a expression is shown in panel C, and the
summary results are shown in panel D (1 dot 5 1 donor). (E) Representative density plot of HLA-E expression in primary leukemic AML blasts. (F) Summary of HLA-E
expression in primary leukemic AML blasts (n 5 5). (G) Flow cytometry analysis of CD94, NKG2A, and NKG2C in CD561 ILC1-like cells from AML patients at diagnosis
(n 5 3-10) and HDs (n 5 5-17). One dot 5 1 donor. Statistical tests used: panels A-B,D,G: Mann-Whitney U test. **P , .01, ***P , .001, ****P , .0001.
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Figure 5. CD561 ILC1-like cell cytotoxicity is restored in AML patients during remission and is modulated by blasts and TGF-b1. (A) Comparison of peripheral
blood (PB) CD561 ILC1-like cell relative frequencies in AML patients at diagnosis and during remission (n 5 12). (B) Comparison of PB CD561 ILC1-like cell frequencies in
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cells might continue to promote surveillance of tumorigenesis or
microbial infections in settings of waning antitumor or antimicrobial
cell-mediated immunity. These observations further support the
hypothesis that triggering these cells in patients with cancer might
help to restrict tumor burden.
Although CD561 ILC1-like cells can secrete cytokines, their main
function resides in their KIR-independent cytotoxic activity. Uncon-
trolled CD561 ILC1-like cell activities might be limited by NKG2A/
CD94, whereas NKp30, NKp80, and TRAIL are the main receptors
conferring cytotoxic potential. We previously described that NKp30
overexpression in ILC2 in patients with acute promyelocytic leukemia39
is linked to their hyperactivity. NKp80 has been studied in the
context of NK cell maturation31 and has been described as an NK
cell coactivating receptor,40 but no reports regarding its expression
and role in human ILCs are available. Our results suggest that its
presence might be relevant in the context of Activation-Induced C-type
Lectin1 targets. Finally, unconventional Eomes2 group 1 ILCs have
been reported to express TRAIL in the liver and exert TRAIL-dependent
cytotoxicity.41-43 Here, we show that the CD561 ILC1-like cell cytotoxic
machinery is impaired in AML patients. Therefore, by therapeutically
activating the NKp30, NKp80, and TRAIL pathways and inhibiting
NKG2A/HLA-E interactions, the cytotoxicity of CD561 ILC1-like
cell might be restored, and subsequently AML could be controlled.
Hence, the administration of the checkpoint inhibitor anti-NKG2A
antibody44 could unleash hypofunctional CD561 ILC1-like cells in AML
patients for whom alloreactive NK cell donors cannot be found. Future
studies comparing the activity of anti-NKG2A antibodies on CD561
ILC1-like cells and NKs in AML patients with HLA-E1 and HLA-E2
blasts will provide valuable insights on this regard.
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Figure 6. CD561 ILC1-like cells are present in
NK-cell preparations used for NK-cell transfer
therapy. (A) Representative density plots of the
extracellular flow cytometry panel used to identify
the ILC subsets in CD32 CD561-enriched frac-
tions of HD PBMCs. (B) Proportions of total ILCs
(Lineage2CD1271), CD56bright CD162, and
CD56dim CD161 NKs in NK-cell transfer therapy
products from HD PBMCs (n 5 10). (C) NK
marker expression on PB CD561 ILC1-like cells
before and after the CD32 CD561 enrichment
(n 5 5).
Figure 5. (continued) paired AML patient samples at diagnosis and during remission (n 5 7). (C) Comparison of CD561 ILC1-like cell AML patients at diagnosis or during
remission to determine the degranulation capacity after a 4-hour coculture of ILC/NK-enriched PBMCs with K562 (ratio E:T 1:1), anti-CD107a, and Golgistop (remission: n 5 3).
(D) Comparison of TRAIL, NKp30, and NKp80 expression in PB CD561 ILC1-like cells from AML patients at diagnosis (n 5 10) and during remission (n 5 5). (E-F) PBMCs from
AML patients at diagnosis were depleted of CD331 blasts and cultured for 24 hours in complete medium. (E) Extracellular flow cytometry was performed to assess TRAIL, NKp30,
and NKp80 expression in CD561 ILC1-like cells (n 5 6-7). Correlation between TRAIL expression after the 24 h culture and blast frequencies in PB (n 5 4, panel F). (G) PBMCs
from HDs were enriched in ILC/NK cells and cultured for 24 hours with medium only or supplemented with rhTGF-b1 at 5 ng/mL (n 5 8). TRAIL, NKp30, and NKp80 expression
was assessed by flow cytometry after the culture. (H) Heat map of z scores of expression levels of genes encoding TGF-b receptors in ILCs and cNKs (n 5 3). (I) Free/total TGF-
b1 ratio in sera from HDs and AML patients. Sera with concentrations above the limit of detection of the assay are shown (HDs: n 5 9, AML patients: n 5 11). (J) Kaplan-Meier
overall survival analysis based on TGF-b1 expression in AML patients from The Cancer Genome Atlas program (TCGA) (n 5 125). We excluded patients presenting a t(15;17)
translocation (ie, patients with acute promyelocytic leukemia as classified according to the 2017 European LeukemiaNet recommendations36) from our analysis since this condition
represents a distinct AML pathophysiological entity. Statistical tests used: panels C-D: Mann-Whitney unpaired U test; panels E,G: Wilcoxon paired t test; panel F: Spearman
correlation; panel J: difference in overall survival (OS) between AML patients with high (n 5 64) or low (n 5 61) TGF-b1 expression based on TCGA data. *P , .05, ***P , .001.
3684 SALOME´ et al 26 NOVEMBER 2019 x VOLUME 3, NUMBER 22
Furthermore, our data show that in vitro removal of leukemic blasts
contributes to the recovery of TRAIL expression in CD561 ILC1-like
cells. This observation might partially explain the in vivo restored
expression of TRAIL in CD561 ILC1-like cells in AML patients during
remission. It has been recently reported that TGF-b controls TRAIL
expression in salivary gland ILCs,45 whereas it has been previously
reported that leukemic-blast derived microvesicles containing TGF-
b1 inhibit TGF-b–receptor expressing immune cells in AML.46 Our
findings that TGF-b1 in vitro induces the downregulation of TRAIL
and NKp30 in CD561 ILC1-like cells and that elevated TGF-b1
concentrations are associated with patients’ poor survival suggest
that blocking TGF-b1 using small molecule inhibitors, such as
galunisertib, might restore the CD561 ILC1-like cell activity.
However, future studies directly assessing the impact of TGF-b1
inhibitors on HDs and AML patients’ CD561 ILC1-like cell cytotoxicity
should be performed to confirm these correlative observations. Then,
coadministration with anti-NKG2A antibodies might heighten the
therapeutic benefits with rather favorable toxicity profiles as suggested
by preclinical studies using combinations of TGF-bRI inhibition and
checkpoint blockade.47 Furthermore, AML blasts have been shown to
impair NK cell functions in AML patients through the secretion of AhR
ligands.38 Our results argue that these ligands also partially impair
CD561 ILC1-like cell functions and might thus be involved in their
decreased cytotoxicity in AML patients.
It has been reported that NKp46 triggers TRAIL expression in ILC1
in mice.48 However, in AML patients, we found no correlation
betweenNKp46 and TRAIL expression in CD561 ILC1-like cells (n5 8,
P5 .76), suggesting that distinct mechanisms underlie the regulation
of receptor expression across species. The observed downregulation
of activating receptors might be due to the long-lasting contact with
their ligands,49 ultimately leading to CD561 ILC1-like cell dysfunc-
tion. Alternatively, the overexpression of inhibitory receptors might
contribute to CD561 ILC1-like cell impaired function in AML patients.
Although the expression of “common” immune checkpoints (eg,
PD-1, CTLA-4, and BTLA) was absent in CD561 ILC1-like cells
from both the HDs and the patients, we observed significant levels
of IL-1R8 in the HDs’ CD561 ILC1-like cells (data not shown). IL-1R8
represents a novel immune checkpoint that was shown to negatively
regulate NK cell maturation and antiviral and antitumor functions in
mice, but it has not been reported in human ILCs to date.50 Future
studies are needed to assess the impact of this receptor on human
CD561 ILC1-like cells.
Finally, given that the CD56 marker is a major discriminator of the
CD561 ILC1-like cell phenotype from that of helper ILCs, we
hypothesized and confirmed that CD561 ILC1-like cells are
present in the CD32CD561-enriched NK cell fractions infused in
AML patients. Since several studies have demonstrated that
patients’ responses can be influenced by the composition of the
NK cell graft,51 the impact of the CD561 ILC1-like cell presence on
parameters, such as relapse and survival, urgently needs to be
investigated. In that regard, we envisage to characterize and
quantify CD561 ILC1-like cells in NK preparations that will be
transferred to patients to determine the correlation with the clinical
outcome (Clinical trial Bologna NKAML Trial 035/2017/0/Sper).
Triggering the CD561 ILC1-like cell compartment in these enriched
fractions by anti-NKG2A, monoclonal antibodies could potentiate
their KIR-independent antileukemic action. Alternatively, enriching
NK fractions with the CD561 ILC1-like cell compartment or ex vivo
expanding CD561 ILC1-like cells similarly to NK cell expansion,
which has been proven to be safe and feasible,52 might help obtain
better clinical results without the need of KIR-mismatch.
Overall, this work highlights the importance of improving our
knowledge of this CD1271 c-Kit2 CD561 population to help
select the best donors for patients and maximize the effects of
immunotherapy in AML.
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